logo
Peloton Stock Has Soared 256% From Its 52-Week Low. Is It Too Late to Buy?

Peloton Stock Has Soared 256% From Its 52-Week Low. Is It Too Late to Buy?

Yahoo24-02-2025

Peloton Interactive (NASDAQ: PTON) stock was a pandemic darling. It reached a record high of $162 at the end of 2020, on the back of surging sales for the company's at-home exercise equipment, which helped fitness enthusiasts stay active in the midst of lockdowns and social restrictions.
But sales plummeted once social conditions returned to normal, which sent Peloton's losses skyrocketing. On a few occasions since 2022, there were even concerns that the company wouldn't survive, prompting a management shakeup and a major shift in strategy.
Some of those changes are starting to bear fruit at the bottom line, and Peloton stock has recently soared by 256% from its 52-week low. However, with a stock price of just $9.63 as of this writing, it remains 94% below its record level from 2020. Is this the start of a long-term recovery, or will the recent upside fizzle out?
At the beginning of 2022, Peloton appointed Barry McCarthy as CEO. He brought a wealth of experience from his time as an executive at Spotify and Netflix. His primary focus was securing Peloton's survival by dramatically cutting costs and creating new opportunities to generate revenue.
During his two-year tenure (which ended in 2024), McCarthy slashed half of Peloton's workforce, offshored manufacturing for its exercise equipment, and tapped into new sales channels by listing products with third parties like Amazon and Dick's Sporting Goods. He also expanded Peloton's subscription business by creating a new app-based service for fitness enthusiasts who don't use the company's equipment.
In fact, subscriptions now bring in more revenue than equipment sales. But, unfortunately, growth has stalled, with subscription revenue decreasing by 1% year over year during its fiscal 2025's second quarter (ended Dec. 31, 2024). Churn remains a problem -- the number of connected fitness subscribers shrank 4% during the quarter, to 2.88 million members. Paid app subscribers (those who don't own Peloton's hardware) plunged 19% to 579,000.
Equipment revenue is shrinking at an even faster pace, declining by 20% during Q2 on the back of sluggish sales of flagship hardware products like the Bike, Tread, and Row. According to Peloton's guidance, its total revenue for fiscal 2025 is on track to come in at $2.4 billion. That would represent a drop of 9% from fiscal 2024, marking the fourth consecutive annual decline. This is a serious problem, and I'll explain why in a moment.
Peloton's cost cuts continue to outpace the declines in its revenue, which is driving an improvement at the bottom line. For example, the company's revenue shrank by 3.5% during fiscal 2024, but operating expenses were down 18.2%. The company still lost $551.9 million on a GAAP (generally accepted accounting principles) basis, but that was a massive reduction from its $1.2 billion net loss in fiscal 2023.
That trend continued in the first half of fiscal 2025. Peloton lost just $92.8 million for the six-month period, which was down from $354.1 million in the year-ago period. The improvement was driven by a 27.5% decrease in operating expenses, which outpaced the 5.9% drop in revenue.
The picture looks even better from a non-GAAP perspective. After excluding one-off costs related to things like restructuring, and non-cash expenses like stock-based compensation, Peloton actually delivered $174.2 million in adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) during the first half of fiscal 2025. It isn't "true" profitability because of all the exclusions, but it suggests the company is moving in the right direction.
However, management can't slash costs forever. Repeatedly cutting operating expenses like marketing and research and development hinders the company's ability to attract new customers and release new products, which risks placing its revenue in an irreversible downward spiral. So, while achieving profitability is important, it's not necessarily a huge positive if it's on the back of sharp cost cuts alone without any organic sales growth.
Peloton stock currently trades at a price-to-sales (P/S) ratio of 1.3, which is more than triple where it was in mid-2024. It suggests investors are becoming more confident in the possibility of a positive outcome from this difficult period. However, Peloton's P/S ratio is at rock bottom compared to where it was a few years ago, which means this recovery might still have legs if the company continues turning things around.
Still, no investor likes owning a shrinking business, and that's exactly what Peloton is right now. The company is in a relatively secure position because it's generating positive adjusted EBITDA, and it has $829 million in cash and equivalents on its balance sheet. However, it also has $948 million worth of debt which will have to be addressed in the future.
My concern is that Peloton won't be able to deliver organic revenue growth from here, and it will eventually run out of costs to cut, which will lead to ballooning losses once again.
Peloton's new CEO, Peter Stern, officially stepped into the job on Jan. 1. He most recently worked at Ford Motor Company, but he also spent six years as the Vice President of services at Apple, where he managed products like Apple TV and Apple Fitness. Hopefully, he can use his experience to build on McCarthy's work and chart a path back to growth.
With that said, I suggest avoiding the stock until that moment comes.
Before you buy stock in Peloton Interactive, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Peloton Interactive wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $823,858!*
Now, it's worth noting Stock Advisor's total average return is 917% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of February 21, 2025
John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Anthony Di Pizio has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon, Apple, Netflix, Peloton Interactive, and Spotify Technology. The Motley Fool has a disclosure policy.
Peloton Stock Has Soared 256% From Its 52-Week Low. Is It Too Late to Buy? was originally published by The Motley Fool

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Honeywell Finalizes Sundyne Acquisition to Boost Its Process Industry Strength
Honeywell Finalizes Sundyne Acquisition to Boost Its Process Industry Strength

Yahoo

time15 minutes ago

  • Yahoo

Honeywell Finalizes Sundyne Acquisition to Boost Its Process Industry Strength

Honeywell International Inc. (NASDAQ:HON) is one of the best Dow stocks to invest in. On June 9, the company announced that it had finalized its $2.16 billion all-cash acquisition of Sundyne from private equity firm Warburg Pincus. Sundyne, known for its advanced pumps and gas compressors used in process industries, is expected to contribute immediately to Honeywell International Inc. (NASDAQ:HON)'s revenue growth, segment margins, and adjusted earnings per share during the first full year of ownership. Sundyne brings strong customer relationships and top-tier technology, which are expected to enhance Honeywell UOP's presence in areas like refining, petrochemicals, LNG, and clean energy. Integrated with the Honeywell Forge platform, the combined offering strengthens Honeywell's position in the energy transition by providing a comprehensive, scalable solution. This acquisition comes on the heels of Honeywell International Inc. (NASDAQ:HON)'s recent announcement to spin off its Aerospace Technologies and Solstice Advanced Materials units, moves aimed at creating three separate publicly traded companies, each with focused strategies and growth opportunities. Since December 2023, Honeywell has pursued several strategic initiatives to boost organic growth and streamline its operations, including $13.5 billion in value-enhancing acquisitions. The company operates globally across a wide range of industries. HON has surged by over 7% in the past 12 months. While we acknowledge the potential of HON as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

How major US stock indexes fared Wednesday, 6/11/2025
How major US stock indexes fared Wednesday, 6/11/2025

Yahoo

time19 minutes ago

  • Yahoo

How major US stock indexes fared Wednesday, 6/11/2025

Wall Street's rally stalled after stocks climbed back within 2% of their all-time high. The S&P 500 slipped 0.3% Wednesday, marking its first drop in four days. The Dow Jones Industrial Average ended little changed, and the Nasdaq composite lost 0.5%. The action was stronger in the bond market, where Treasury yields eased after a report showed inflation ticked up by less last month than economists expected. That raised expectations for the Federal Reserve to cut interest rates later this year. Markets didn't react much to the conclusion of two days of trade talks between the U.S. and China. On Wednesday: The S&P 500 fell 16.57 points, or 0.3%, to 6,022.24. The Dow Jones Industrial Average fell 1.10 points, or less than 0.1%, to 42,865.77. The Nasdaq composite fell 99.11 points, or 0.5%, to 19,615.88. The Russell 2000 index of smaller companies fell 8.17 points, or 0.4%, to 2,148.23. For the week: The S&P 500 is up 21.88 points, or 0.4%. The Dow is up 102.90 points, or 0.2%. The Nasdaq is up 85.92 points, or 0.4%. The Russell 2000 is up 15.99 points, or 0.7%. For the year: The S&P 500 is up 140.61 points, or 2.4%. The Dow is up 321.55 points, or 0.8%. The Nasdaq is up 305.08 points, or 1.6%. The Russell 2000 is down 81.92 points, or 3.7%. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Allarity Therapeutics Announces Changes to Board of Directors
Allarity Therapeutics Announces Changes to Board of Directors

Yahoo

time24 minutes ago

  • Yahoo

Allarity Therapeutics Announces Changes to Board of Directors

TARPON SPRINGS, Fla., June 11, 2025 -- Allarity Therapeutics, Inc. ('Allarity' or the 'Company') (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology—today announced that Jesper Høiland has been appointed to join the Company's Board of Directors. He will be replacing Joseph Vazzano, who will resign from the Board effective on June 30, 2025, following his valuable contributions to Allarity's development over the past two years. Mr. Høiland is already well-acquainted with Allarity's mission and operations, having served as a strategic consultant to the Company since October 2024. Jesper Høiland is a highly respected industry leader with more than 30 years of experience in global pharmaceutical commercialization and executive leadership. He previously served as President and EVP of Novo Nordisk's U.S. operations, where he led major product launches, pricing strategies, and infrastructure expansion. In addition, he held senior executive roles as President and CEO of Radius Health and as Global Commercial Officer at Ascendis Pharma. Mr. Høiland currently serves as Chairman of SciBase Holding AB and is a board member of ALK-Abello A/S and Flen Health SA. 'We are pleased to welcome Jesper Høiland to the Allarity Board during a period of growing clinical momentum,' said Jerry McLaughlin, Chairman of the Board of Directors at Allarity Therapeutics. 'On behalf of the entire Board, I would also like to thank Joseph Vazzano for his contributions to Allarity. His financial expertise and thoughtful guidance helped strengthen our governance and operational focus during a critical time. We are grateful for his service and wish him the very best in his ongoing endeavors.' Thomas Jensen, CEO of Allarity Therapeutics, added: 'Since Jesper started working with us in his consultancy capacity, I have several times benefited from his experience and strategic advice. His deep understanding of how to prepare for the commercialization phase of an investigational drug, his extensive global network—built over decades at Novo Nordisk—and his proven leadership during periods of strategic transition at Radius Health will certainly be valuable to Allarity. It is very positive that he will now be even more closely engaged with the Company, as we prepare for the next phases of clinical development and potential later commercialization of stenoparib.' About StenoparibStenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. At present, tankyrases are attracting significant attention as emerging therapeutic targets for cancer, principally due to their role in regulating the WNT signaling pathway. Aberrant WNT/β-catenin signaling has been implicated in the development and progression of numerous cancers. By inhibiting PARP and blocking WNT pathway activation, stenoparib's unique therapeutic action shows potential as a promising therapeutic for many cancer types, including ovarian cancer. Allarity has secured exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. and was formerly known under the names E7449 and the Drug Response Predictor – DRP® Companion DiagnosticAllarity uses its drug-specific DRP® to select those patients who, by the gene expression signature of their cancer, may have a high likelihood of benefiting from a specific drug. By screening patients before treatment, and only treating those patients with a sufficiently high, drug-specific DRP score, the therapeutic benefit rate may be enhanced. The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes. DRP is based on messenger RNA expression profiles from patient biopsies. The DRP® platform has shown an ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients across dozens of clinical studies (both retrospective and prospective). The DRP platform, which may be useful in all cancer types and is patented for dozens of anti-cancer drugs, has been extensively published in the peer-reviewed Allarity TherapeuticsAllarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. The Company is focused on development of stenoparib, a novel PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP® technology to develop a companion diagnostic that can be used to select those patients expected to derive the greatest clinical benefit from stenoparib. Allarity is headquartered in the U.S., with a research facility in Denmark, and is committed to addressing significant unmet medical needs in cancer treatment. For more information, visit Follow Allarity on Social MediaLinkedIn: Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company's current expectations or forecasts of future events. The words 'anticipates,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intends,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predicts,' 'project,' 'should,' 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding the anticipated contributions of Jesper Høiland to Allarity's strategic direction; expectations about the Company's clinical and commercial development of stenoparib; the Company's ability to benefit from enhanced leadership and governance; and the potential future impact of board changes on corporate strategy and stakeholder value. Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to risks related to changes in leadership not yielding expected outcomes; uncertainties around clinical development timelines; risks that clinical data may not support regulatory approval or commercial viability; and the general risks associated with operating a clinical-stage biopharmaceutical company. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled 'Risk Factors' in our Form 10-K annual report filed with the Securities and Exchange Commission (the 'SEC') on March 31, 2025, available at the SEC's website at and as well as discussions of potential risks, uncertainties and other important factors in the Company's subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law. ### Company Contact: investorrelations@ Media Contact: Thomas Pedersen Carrotize PR & Communications +45 6062 9390 tsp@ Attachment Allarity Therapeutics Press Release - Announces Changes to Board of DirectorsError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store